Product Reports Resources Pricing Login Book a demo

Voyager Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2014 · IPO 2015

Gene therapies for neurological diseases crossing blood-brain barrier.

Valuation $76M
Revenue $39M

Investors

11 investors on Voyager Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Series B+ 10 investors entered at this stage
Wellington Management
Casdin Capital
Brookside Capital
PFM Health Sciences
University of Massachusetts Medical School
Fidelity Investments
University of California
San Francisco
Foresite Capital
Stanford University

Global footprint

Where Voyager Therapeutics has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States99.3%
🇲🇽 Mexico0.7%
2 countries shown
Web traffic by country
11K monthly visits
across markets
🇺🇸 United States78.2%
🇬🇧 United Kingdom7.3%
🇮🇳 India6.4%
🇦🇺 Australia5.5%
Top 4 markets shown

Talent graph

The shape of Voyager Therapeutics's talent

Dealroom maps Voyager Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

8 standout operatorsDealroom-flagged across the org
5 AI specialistsincl. 1 core researchers
161 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Voyager Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$42M patent portfolio · 80 active families

Estimated portfolio value
$42M
55.3% of market cap · comparable to top peer Spark Therapeutics ($46M)
80 active patent families
Where Voyager Therapeutics innovates Adeno-associated virusBiochemistryBioinformaticsCapsidCell biology

Where Voyager Therapeutics concentrates vs peers

Each axis is a top-10 topic across Voyager Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Voyager Therapeutics

An AI-synthesized read of the highest-engagement posts about Voyager Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Voyager Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.